Analyst: Bio-Techne's growth plan still includes M&A

Bio-Techne's growth strategy still includes M&A

Bio-Techne may be waiting for the mergers and acquisitions market to calm before it resumes its acquisition strategy. The Minneapolis-based maker of biotechnology reagents, instruments and clinical diagnostic products made six deals in 2014 but has announced only one so far in 2015.

Leerink analyst Dan Leonard wrote in a research note last week that Bio-Techne's growth is dependent on overall organic revenue growth, China's increased funding on life sciences and health care and a more aggressive merger and acquisition strategy.

Leonard estimates that Bio-Techne has 80 acquisition targets in mind in a variety of sizes and levels of actionability. He acknowledges that market conditions may force the company to focus on immediate internal growth prospects before looking ­outside.

"We expect executing on acquisitions will remain a prominent part of Bio-Techne's strategy," Leonard wrote. "However, we believe that larger acquisitions might be more difficult to consummate in the current choppier market environment."

Patrick Kennedy

Holding firm on UnitedHealth Group

The Minnetonka-based diversified health company reported $1.65 earnings per share for the quarter, a penny above analyst consensus estimates.

James maintained her buy rating of "outperform" and a $143 per share price target, writing: "Our valuation is based on a modestly positive outlook for the multiline group. We continue to watch for signs of cost increases; until these materialize we believe the group will trade in-line with the S&P 500."

Patrick Kennedy

Demand for key Polaris addition

The centerpiece of Polaris Industries' 2016 model year is the RZR XP Turbo, a side-by-side off-road vehicle that features a 925 cc engine and 144 horsepower. That vehicle was announced months ago and Polaris is starting to see a sales boost. Medina-based Polaris recently announced more additions to the 2016 lineup, including a four-seat version of the RZR XP Turbo.